Tumor Markers in Prostate Cancer;Tumormarker beim Prostatakarzinom

LaboratoriumsMedizin

Volumn 25, Issue 9-10, 2001, Pages 337-342

  Reiter, W ^a   Oberneder, R ^b   Schmeller, N ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Landeskrankenanstalt Salzburg ^*  (Austria)

Author keywords

benign hyperplasia of the prostate; free PSA (f PSA); Freies PSA (f PSA); Gutartige Hyperplasie der Prostata; Prostata spezifisches Antigen (t PSA); Prostatakrebs; prostate cancer; prostate specific antigen (t PSA); tumor marker; Tumormarker

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BENIGN TUMOR; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; MALE; MEDICAL DECISION MAKING; MORTALITY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW;

EID: 0035185786     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labm.2001.25.9-10.337     Document Type: Article

References (65)

1. Hölzl, D. Epidemiologic des Prostatakarzinoms. Fortschr Med 1991;109 (26):521-5.
2. Altwein, JE, Rübben, H. Urologie. 3. Auflage. Ferdinand Enke Verlag, Stuttgart 1991: 233.
3. Hölzl, D, Klamert, A, Schmidt, M. Krebs: Häufigkeiten, Befunde und Behandlungergebnisse; Perspektiven für die Krebsregister-diskussion und eine quantitative klinisch-epidemiologische Onkologie aus dem Tumorregister München. W Zuckschwerdt Verlag, München. Bern, Wien, New York 1996: 361.
4. Thüroff, JW. Prostatakarzinom. In: Urologische Differential-diagnose. Georg Thieme Verlag, Stuttgart, New York 1995: 313-314,333-4.
5. Anonymous. Tumour markers in prostate cancer: EGTM recommendations. Anticancer Res 1999;19:2799-801.
6. Barry, MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001;344 (18): 1373-7.
7. Wang, MC, Papsidero, LD, Kuriyama, M, Valenzuela, LA, Murphy, GP, Ghu, TM. Prostate antigen; a new potential marker for prostatic cancer. Prostate 1981;2:89–96.
8. Pollen, JJ, Dreilinger, A. Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral glands. Urology 1984;23:303-4.
9. Ablin, RJ, Soanes, WA, Bronson, P, Witebsky, E. Precipitating antigens of the normal human prostate. J Reprod Fertil 1970;22: 573-4.
10. Wang, MC, Valenzuela, LA, Murphy, GP, Chu, TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17:159-63.
11. Papsidero, LD, Wang, MC, Valenzuela, LA, Murphy, GP. Chu, TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980:40:2428-32.
12. Stenmann, UH. Leinonen, J, Alfthan, H, Rannikko, S, Tukkanen, K, Alfthan, O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of the prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991:51:222-6.
13. Lilja, H., Christensson, A., Dahlen, U., Matikainen, MT, Nilson, O., Pettersson, K., Lövgren, T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991: 37:1618-25.
14. Catalona, WJ, Smitli, DS. Comparison of different serum prostate specific measures for early prostate cancer detection. Cancer 1994:74:1516-8.
15. Partin, AW, Kelly, CA, Subong, ENP, Walsh, PC, Chan, DW, Wang, TJ, Rittenhouse, HG, Wolfert, RL, Norton, KC, Mc Cormack, R. Measuremant of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4 and 10 ng/ml. J Urol 1995; 153:295A
16. Prestigiacomo, AF, Stamey, TA. Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 1995;55(Suppl. 221):323-4.
17. Catalona, WJ, Smith, DS, Wolfert, RL, Wang, TJ, Rittenhouse, HG, Ratliff, TL, Nadler, RB. Evaluation of the percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995:274(18): 1214-20.
18. Mitrunen, K, Pettersson, K, Piironen, T, Björk, T, Lilja, H, Lövgren, T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995,41 (8): 1115-20.
19. Bangma, CH, Kranse, R, Blijenberg, BG, Schroeder, FH. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific antigen ratio, age-specific reference ranges, and PSA density. Urology 1995:46:779-84.
20. Prestigiacomo, AF, Lilja, H, Pettersson, K, Wolfert, RL, Stamey, TA. A comparison of the free fraction of serum prostate specific antisen in men with benign and cancerous prostates: the best case senario. J Urol 1996;156:350-4.
21. Reiter, W, Stieber, P, Schmeller, N, Nagel, D, Hofmann, K, Fateh-Moghadam, A. Total and free PSA: A methodical and clinical evaluation of five assays. Anticancer Res 1997:17:4759-66.
22. Reiter, W. Multicenter study group. The clinical value of the Enzymun-Test for total and free PSA-A multicentre evaluation. Anticancer Res 1999;19:5559-62.
23. 1-Antichymotripsin-PSA (ACT-PSA): A useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate? Anticancer Res 1997:17:4767-70.
24. Wirth, MP, Frohmüller, HGW. Prostate specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases. Eur Urol 1992;22:27–32.
25. Kontturi, M. Is acid phosphatase (PAP) still justified in the management of prostatic cancer. Acta Oncol 1991;30:169–170.
26. Rittenhouse, HG, Finlay, JA, Mikolajczyk, SD, Partin, AW. Human kallikrein (hK2) and prostate-specific anigen (PSA): two closely related, but distinct, kallkreins in the prostate. Crit Rev Clin Lab Sci 1998;53:275–368.
27. Horoszewicz, JS, Kawinski, E, Murphy, GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.Anticancer Res 1987;7:927-35.
28. Wright, GL Jr., Haley, C, Beckett, ML, Schellhammer, PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant tissue. Urol Oncol 1995;1:18–22.
29. Silver, DA, Pellicer, I, Fair, WR, Heston, WD, Cordon-Cordo, C. Prostate-specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res 1997:3:81-5.
30. Rochon, YP, Horoszewicz, JS, Boynton, AL, Holmes, EH, Barren, RJ, Erickson, SJ, Kenny, GM, Murphy, GP. Western blot assay for prostae-specific membrane antigen in serum of prostate cancer patients. Prostate 1994;25:219-23.
31. Oesterling, JE. Prostale specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate, J Urol 1991;145:907-23.
32. ndedition: 29–31.
33. Stamey, TA, Freiha, FS, Me Neal, JE, Redwine, EA, Whittemore, AS, Schmid, HP. Localized prostate cancer. Relationship to tumour volume to clinical significance for treatment of prostate cancer. Cancer 1993:71(Suppl. 3):933-9.
34. Smith, RA, von Eschenbach, AC, Wender, R. American Cancer Society guidelines for the early detection of Cancer: update of early detection guidlines for prostate, colorectal, and endometrial cancer. CA. Cancer J Clin 2001:51:38–75.
35. American College of Physicians. Screening for prostate cancer. Ann. Intern. Med. 1997:126: 480-4.
36. American Urological Association. Prostate-specific antige (PSA) best practice policy. Oncology (Huntingt) 2000:14:267-72, 277-78, 280.
37. Veneziano, S, Pavlica, P, Querze, R, Nanni, G, Lalanne, MG, Vecchi, F. Correlation between. prostate specific antigen and prostate volume evaluated by transrectal ultrasonography: usefulnėss in diagnosis of prostate cancer. Eur Urol 1990:18:112-6.
38. Benson, MC, Whang, IS, Olsson, CA, Mc Mahon, DJ, Cooner, WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-21.
39. Babaian, RJ, Miyashita, H, Evans, RB, Ramirez, El. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol 1992:147:837-40.
40. Gann, PH, Hennekens, CH, Stampfer, MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995;273:289-94.
41. Schmid, HP. Prostate specific antigen doubling time in the diagnosis and follow-up of patients with prostate cancer. Tumor Marker Update 1996:8:71-7.
42. Paul, R, Breul, J, Hartung, R. Prostate-specific antigen density and age specific prostate-specific antigen values: the solution of prostate cancer screening? Eur Urol 1995;27:286-91.
43. Etzioni, R, Shen, Y, Petteway, JC, Brawer, MK. Age-specific prostate-specific antigen: a reassessment. Prostate Suppl 1996; 7:70-7.
44. Benson, MC, Wang, IS, Pantuck, A, Ring, K, Kaplan, SA, Olsson, CA, Cooner, WH. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-6.
45. Stamey, TA, Yang, N, Hay, AR, Mc Neal, JE, Freiha, FS, Redwine, E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med 1987;317:909-16.
46. Seaman, E, Whang, IS, Olsson, CA, Katz, A, Cooner, WH, Benson, MC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin N Amer 1993;20:653-63.
47. Carter, HB, Pearson, JD, Metter, J, Brant, LJ, Chan, DW, Andre, R, Fozard, JLO, Walsh, PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
48. Carter, HB, Morell, CH, Pearson, JD. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostatic disease. Cancer Res 1992;52:3323-8.
49. Oesterling, JE, Jacobsen, SJ, Chute, CG, Guess, HA, Girman, CJ, Panser, LA. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-4.
50. Oesterling, JE, Martin, SK, Bergstrahl, EJ, Lowe, FC. The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57–60.
51. Ruckle, HC, Klee, GG, Oesterling, JE. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response of therapy. Mayo Clin Proc 1994;69:69–79.
52. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidlines for PSA following radiation therapy. Int J Rad Oncol Biol Phys 1997; 37:1035-41.
53. Polascik, TS, OesterIing, JE, Partin, AW. Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol 1999:162:293–306.
54. Me Cormack, RT, Rittenhouse, HG, Finlay, JA, Sokoloff, RL, Wang, TJ, Wolfèrt, RL, Lilja, H, Oesteriing, JE. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729-44.
55. Zanctti, G, Trinchieri, A, Del Nero, A, Montanari, E, Cogni, M, Colombo, F, Buzzetti, V, Austoni, E. Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma. Eur Urol (Suppl); 1992;21:96-8.
56. Stamey, TA, Kabalin, JN, Ferrari, M, Yang, N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989;141; 1088-90.
57. Arai, Y, Yoshiki, T, Yoshida, O. Prognostic significance in endocrine treatment for prostatic carcinoma. J Urol 1990;144:1415-9.
58. Matzin, H, Eber, P, Todd, B, van der Zwaag, R, Soloway, MS. Prognostic significance of changes on prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992;70:2302-9.
59. Collins, GN, Martin, PJ, Wynn-Davies, A, Brooman, PJ, O'Reilly, PH. The effekt of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free to total prostate specific antigen ratio in clinical practice. J Urol 1997;157:1744-7.
60. Tchetgen, MB, Song, JT, Strawderman, M, Jacobsen, SJ, Oesterling, JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996;47:7–33.
61. Herschman, JD, Smith, DS, Catalona, WJ. Effect of ejaculation on serum total and free prostate specific antigen concentrations. Urology 1997;50:239-43.
62. Nadler, RB, Humphrey, PA, Smith, DS, Catalona, WJ, Ratliff, TL. Effect of inflammmation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407-13.
63. Semjonow, A, Brandt, B, Oberpenning, F, Roth, S, Hertle, L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen value. Prostate (Suppl) 1996: 7:3–16.
64. Semjonow, A, Oberpenning, F, Brandt, B, Zechel, C, Brandau, W, Hertle, L. Impact of the free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 1996;48(Suppl 64):10–15.
65. Price, CP, Allard, J, Davies, G, Dawnay, A, Duffy, AJ, France, M, Mandarino, G, Ward, AM, Patel, B, Sibley, P, Sturgeon, C. Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isofomis in a screening programme for prostate cancer. Ann Clin Biochem 2001;38:188–216.